AI주식인사이트AI Stock Insight
C

나이벡

138610KOSDAQ

47.5 / 100

Reference Date: 2026-10-23

Financial Score18.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 6.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Nabix operates in the fields of bio-regenerative materials, peptide pharmaceuticals, and oral health products, holding global certifications such as FDA, CE, and NMPA, and selling products worldwide. The company is focusing on expanding its global market through the commercialization of new products like PeptiCol EZgraft and obtaining European MDR certification, while also developing early diagnosis kits and treatments for periodontal diseases.

Number of Employees

93people

Average Salary

59.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
35.94Industry Average 15.000.0Point

2.4x industry avg (risky)

PBR
3.71Industry Average 1.200.0Point

3.1x industry avg (risky)

ROE
11.89Industry Average 8.004.0Point

In line with industry avg

Debt Ratio
11.70Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲44.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲40.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -13.0% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 14,950Won52-week high 52,30052-week low 12,200
1-month return4.0Point

1m +6.03% (slight rise)

Volume trend2.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0